In Brief: Chantal Pharmaceutical
This article was originally published in The Rose Sheet
Executive Summary
Chantal Pharmaceutical: Nets $6.8 mil. in a July 24 private placement of 1 mil. shares of common stock and 500,000 Series C Voting Convertible Preferred Stock shares (after payment of a 7.5% placement fee), the company announces Aug. 8. Chantal said the funds "will be used for general corporate purposes." In addition, Los Angeles-based Chantal expects its recently acquired lab in Arizona to be operational this fall. According to the firm, the lab will "triple Chantal's production capacity." The firm markets Chantal ethocyn-based skin care products ("The Rose Sheet" Nov. 28, In Brief) and is researching and developing both topical and systemic pharmaceutical products "for the treatment of androgen-mediated disorders...[and] certain cancers"...